Akebia Therapeutics, Inc.

As of June 30, 2026, Akebia Therapeutics, Inc. carries a market capitalization of 269.57M, placing it among publicly traded companies globally. Its enterprise value stands at 181.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Akebia Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Akebia Therapeutics, Inc. has 271.74M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.38, and the price-to-book ratio stands at 12.31.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 181.53M versus a market cap of 269.57M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Akebia Therapeutics, Inc. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 219.72, indicating elevated leverage, while an interest coverage ratio of -0.78 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Akebia Therapeutics, Inc. posted a negative return on equity (ROE) of -109.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.53, reflecting losses generated across the asset base. The company generates approximately 1.01M in revenue per employee across its workforce of 190.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.00 indicates how many times Akebia Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Akebia Therapeutics, Inc. recorded 1.59M in income tax expense. The company reported a pretax loss of -24.37M and -25.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Akebia Therapeutics, Inc.'s stock has declined approximately 80.76% over the past 52 weeks. The 50-day moving average sits at 0.76, while the 200-day moving average is 1.00.

Over the twelve months ended June 30, 2026, Akebia Therapeutics, Inc. generated 191.74M in revenue and converted that into -25.97M in net income, yielding earnings per share of -0.10. EBITDA reached -11.88M, while operating income came in at -11.54M.

As of June 30, 2026, Akebia Therapeutics, Inc. holds 136.15M in cash and equivalents against 48.11M in total debt, resulting in a net debt position of -92.77M. Total book value stands at 21.90M, with working capital of 60.12M providing operational flexibility.

Akebia Therapeutics, Inc. produced 36.37M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.13M in capital expenditures, free cash flow totaled 35.24M - equivalent to 0.13 per share.

Over the twelve months ended June 30, 2026, Akebia Therapeutics, Inc. posted a gross margin of 79.63, reflecting its pricing power and cost economics. The operating margin of -6.02 and net profit margin of -13.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 13.20, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.64, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Akebia Therapeutics, Inc. shareholders.

As of June 30, 2026, Akebia Therapeutics, Inc. has an Altman Z-Score of -6.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.